Ventyx Biosciences shares are trading lower after the company announced results from the Phase 2 trial of VTX002 in patients with moderate-to-severely active ulcerative colitis.
Portfolio Pulse from Benzinga Newsdesk
Ventyx Biosciences announced results from the Phase 2 trial of VTX002 in patients with moderate-to-severely active ulcerative colitis, causing its shares to trade lower.
October 10, 2023 | 12:44 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Ventyx Biosciences' stock is trading lower after the company announced Phase 2 trial results of VTX002.
The announcement of the Phase 2 trial results of VTX002 has led to a decrease in the trading price of Ventyx Biosciences' shares. This suggests that the market may have had higher expectations for the trial results.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100